Quercetin induces insulin secretion by direct activation of L-type calcium channels in pancreatic beta cells. 2013

G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
Département de Pharmacologie Médicale et Toxicologie, Hôpital Lapeyronie, CHRU de Montpellier, Montpellier, France.

OBJECTIVE Quercetin is a natural polyphenolic flavonoid that displays anti-diabetic properties in vivo. Its mechanism of action on insulin-secreting beta cells is poorly documented. In this work, we have analysed the effects of quercetin both on insulin secretion and on the intracellular calcium concentration ([Ca(2+)]i) in beta cells, in the absence of any co-stimulating factor. METHODS Experiments were performed on both INS-1 cell line and rat isolated pancreatic islets. Insulin release was quantified by the homogeneous time-resolved fluorescence method. Variations in [Ca(2+)]i were measured using the ratiometric fluorescent Ca(2+) indicator Fura-2. Ca(2+) channel currents were recorded with the whole-cell patch-clamp technique. RESULTS Quercetin concentration-dependently increased insulin secretion and elevated [Ca(2+)]i. These effects were not modified by the SERCA inhibitor thapsigargin (1 μmol·L(-1)), but were nearly abolished by the L-type Ca(2+) channel antagonist nifedipine (1 μmol·L(-1)). Similar to the L-type Ca(2+) channel agonist Bay K 8644, quercetin enhanced the L-type Ca(2+) current by shifting its voltage-dependent activation towards negative potentials, leading to the increase in [Ca(2+)]i and insulin secretion. The effects of quercetin were not inhibited in the presence of a maximally active concentration of Bay K 8644 (1 μmol·L(-1)), with the two drugs having cumulative effects on [Ca(2+)]i. CONCLUSIONS Taken together, our results show that quercetin stimulates insulin secretion by increasing Ca(2+) influx through an interaction with L-type Ca(2+) channels at a site different from that of Bay K 8644. These data contribute to a better understanding of quercetin's mechanism of action on insulin secretion.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D011794 Quercetin A flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin. 3,3',4',5,7-Pentahydroxyflavone,Dikvertin
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002120 Calcium Channel Agonists Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in VASCULAR SMOOTH MUSCLE and/or CARDIAC MUSCLE cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. Calcium Channel Activators,Calcium Channel Agonists, Exogenous,Calcium Channel Agonist,Exogenous Calcium Channel Agonists,Activators, Calcium Channel,Agonist, Calcium Channel,Agonists, Calcium Channel,Channel Activators, Calcium,Channel Agonist, Calcium,Channel Agonists, Calcium
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001498 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool. BK-8644,Bay R5417,Bay-K-8644,Bay-K-8644, (+)-Isomer,Bay-K-8644, (+-)-Isomer,Bay-K-8644, (-)-Isomer,Bay-K8644,Bay-R-5417,BK 8644,BK8644,Bay K 8644,Bay K8644,Bay R 5417,BayK8644,BayR5417,R5417, Bay

Related Publications

G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
January 2022, Biochemical and biophysical research communications,
G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
September 2009, American journal of physiology. Endocrinology and metabolism,
G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
March 2022, Biochemical and biophysical research communications,
G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
March 2013, Diabetologia,
G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
November 2018, Journal of cellular physiology,
G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
September 2000, The Journal of clinical endocrinology and metabolism,
G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
June 1997, Diabetes,
G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
January 1992, Pflugers Archiv : European journal of physiology,
G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
April 2007, American journal of physiology. Endocrinology and metabolism,
G Bardy, and A Virsolvy, and J F Quignard, and M A Ravier, and G Bertrand, and S Dalle, and G Cros, and R Magous, and S Richard, and C Oiry
January 2018, Frontiers in endocrinology,
Copied contents to your clipboard!